EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC‐CAD Randomized Clinical Trial

Jae-Sung Yu iD, Min-Soo Cho iD, Do-Yoon Kang iD, Jung-Min Ahn iD, Jung-Bok Lee, Yong-Seog Oh, Chang-Hoon Lee iD, Eue-Keun Choi iD, Ji-Hyun Lee iD, Chang-Hee Kwon iD, Gyung-Min Park iD, Hyung-Oh Choi iD und 14 weitere

Journal of the American Heart Association · 07.04.2026 · 15 (7)

DOI: 10.1161/jaha.125.046966 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 07.04.2026. Verfasst von Jae-Sung Yu und 25 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology Asan Medical Center, University of Ulsan College of Medicine Seoul Korea. Hauptthemen laut MEDLINE: Atrial Fibrillation, Pyridines, Thiazoles, Coronary Artery Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paroxysmal atrial fibrillation (AF) is associated with a risk of stroke or systemic embolism similar to nonparoxysmal (persistent or permanent) AF. However, whether the optimal antithrombotic strategy in patients with AF and stable coronary artery disease differs by AF pattern remains uncertain.

Methods

This prespecified substudy of the EPIC‐CAD (Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease) trial compared edoxaban monotherapy with dual antithrombotic therapy (edoxaban plus a single antiplatelet agent) in patients with AF and stable coronary artery disease. Stratified analyses were performed by AF pattern. The primary outcome was net adverse clinical events, defined as a composite of all‐cause death, myocardial infarction, stroke, systemic embolism, unplanned urgent revascularization, major bleeding, or clinically relevant nonmajor bleeding within 12 months.

Results

Among 1040 patients, 575 (55.3%) had paroxysmal and 465 (44.7%) had nonparoxysmal AF. The 12‐month primary outcome rate was similar between paroxysmal and nonparoxysmal AF (10.3% versus 12.2%; adjusted hazard ratio [HR], 1.15 [95% CI, 0.79–1.68]). Edoxaban monotherapy was associated with a significantly lower risk of the primary outcome than dual antithrombotic therapy in both paroxysmal AF (4.6% versus 16.2%; adjusted HR, 0.23 [95% CI, 0.12–0.42]) and nonparoxysmal AF (9.3% versus 15.0%; adjusted HR, 0.56 [95% CI, 0.32–0.87]). No significant interaction was observed between antithrombotic strategy and AF pattern ( P for interaction=0.10).

Conclusions

In patients with AF and stable coronary artery disease, edoxaban monotherapy significantly reduced net adverse clinical events at 12 months compared with dual antithrombotic therapy, irrespective of AF pattern. Registration URL: https://www.ClinicalTrials.gov ; Unique identifier: NCT03718559 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationPyridinesThiazolesCoronary Artery DiseaseFactor Xa InhibitorsStrokePlatelet Aggregation InhibitorsFibrinolytic AgentsHumansFemaleMaleAgedHemorrhageTreatment OutcomeMiddle AgedRisk FactorsDrug Therapy, CombinationTime Factors

Stichwörter der Autor:innen

antithrombotic therapyatrial fibrillationcoronary artery diseaseedoxaban

Substanzen

PyridinesedoxabanThiazolesFactor Xa InhibitorsPlatelet Aggregation InhibitorsFibrinolytic Agents

Autor:innen und Institutionen

  • Division of Cardiology Asan Medical Center, University of Ulsan College of Medicine Seoul Korea.
  • Division of Biostatistics Asan Medical Center, University of Ulsan College of Medicine Seoul Korea.
  • Department of Cardiology Seoul St. Mary's Hospital Seoul Korea.
  • Department of Cardiology Veterans Health Service Medical Center Seoul Korea.
  • Cardiovascular Center, Seoul National University Bundang Hospital Seongnam Korea.
  • Division of Cardiology Konkuk University Medical Center Seoul Korea.

ORCID-Profile: Jae-Sung Yu, Min-Soo Cho, Do-Yoon Kang, Jung-Min Ahn, Chang-Hoon Lee, Eue-Keun Choi, Ji-Hyun Lee, Chang-Hee Kwon, Gyung-Min Park, Hyung-Oh Choi, Kyoung-Min Park, Jong-Min Hwang, Young-Rak Cho, Ji-Hyun Kim, Ki-Won Hwang, Osung Kwon, Ki-Hun Kim, Seung-Jung Park, Gi-Byoung Nam, Duk-Woo Park

Zitieren

APA

Yu, J. S., Cho, M. S., Kang, D. Y., Ahn, J. M., Lee, J. B., Oh, Y. S., Lee, C. H., Choi, E. K., Lee, J. H., Kwon, C. H., Park, G. M., Choi, H. O., Park, K. H., Park, K. M., Hwang, J. M., Yoo, K. D., Cho, Y. R., Kim, J. H., Hwang, K. W., …, & EPIC‐CAD Investigators (2026). Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC‐CAD Randomized Clinical Trial. Journal of the American Heart Association, 15(7). https://doi.org/10.1161/jaha.125.046966

Vancouver

Yu JS, Cho MS, Kang DY, Ahn JM, Lee JB, Oh YS, et al. Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC‐CAD Randomized Clinical Trial. Journal of the American Heart Association. 2026;15(7). doi:10.1161/jaha.125.046966

BibTeX
@article{Yu2026,
  author = {Yu, Jae-Sung and Cho, Min-Soo and Kang, Do-Yoon and Ahn, Jung-Min and Lee, Jung-Bok and Oh, Yong-Seog and Lee, Chang-Hoon and Choi, Eue-Keun and Lee, Ji-Hyun and Kwon, Chang-Hee and Park, Gyung-Min and Choi, Hyung-Oh and Park, Kyung-Ha and Park, Kyoung-Min and Hwang, Jong-Min and Yoo, Ki-Dong and Cho, Young-Rak and Kim, Ji-Hyun and Hwang, Ki-Won and Jin, Eun-Sun and Kwon, Osung and Kim, Ki-Hun and Park, Seung-Jung and Nam, Gi-Byoung and Park, Duk-Woo and EPIC‐CAD Investigators, EPIC‐CAD Investigators},
  title = {Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC‐CAD Randomized Clinical Trial},
  journal = {Journal of the American Heart Association},
  year = {2026},
  volume = {15},
  number = {7},
  doi = {10.1161/jaha.125.046966}
}
Kostenlos starten →